These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14722202)

  • 21. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
    Antoni C; Kalden JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S73-7. PubMed ID: 10589362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab.
    Sidiropoulos PI; Siakka P; Raptopoulou A; Mamoulaki M; Choulaki C; Koutala H; Kouroumali H; Kritikos H; Boumpas DT
    Ann Rheum Dis; 2006 Apr; 65(4):538-41. PubMed ID: 16126800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis.
    van der Bijl AE; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Ten Wolde S; Han KH; van Krugten MV; Allaart CF; Breedveld FC; Dijkmans BA
    Arthritis Rheum; 2007 Jul; 56(7):2129-34. PubMed ID: 17599726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Tatsuki Y; Yano T; Yoshinari T; Abe T; Koike T
    Ann Rheum Dis; 2011 Jul; 70(7):1208-15. PubMed ID: 21478189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy.
    Favalli EG; Marchesoni A; Colombo GL; Sinigaglia L
    Clin Exp Rheumatol; 2008; 26(1):45-51. PubMed ID: 18328146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
    van der Kooij SM; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Güler-Yüksel M; Zwinderman AH; Kerstens PJ; van der Lubbe PA; de Beus WM; Grillet BA; Ronday HK; Huizinga TW; Breedveld FC; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2009 Jun; 68(6):914-21. PubMed ID: 18662933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
    Durez P; Van den Bosch F; Corluy L; Veys EM; De Clerck L; Peretz A; Malaise M; Devogelaer JP; Vastesaeger N; Geldhof A; Westhovens R
    Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study.
    van den Broek M; Klarenbeek NB; Dirven L; van Schaardenburg D; Hulsmans HM; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Aug; 70(8):1389-94. PubMed ID: 21515916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.
    Delabaye I; De Keyser F;
    Arthritis Res Ther; 2010; 12(3):R121. PubMed ID: 20569501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
    St Clair EW; van der Heijde DM; Smolen JS; Maini RN; Bathon JM; Emery P; Keystone E; Schiff M; Kalden JR; Wang B; Dewoody K; Weiss R; Baker D;
    Arthritis Rheum; 2004 Nov; 50(11):3432-43. PubMed ID: 15529377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity.
    Vander Cruyssen B; Durez P; Westhovens R; De Keyser F
    Arthritis Res Ther; 2010; 12(3):R77. PubMed ID: 20459619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
    Hirose W; Nishikawa K; Hirose M; Nanki T; Sugimoto H
    Mod Rheumatol; 2009; 19(1):20-6. PubMed ID: 18762862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.